IP Library Granted Patent US 10,245,261
Granted Patent B2
US 10,245,261 · App. 15/379,696 · Granted Apr 2, 2019

Substituted indol-5-ol derivatives and their therapeutic applications

Inventors: Chunlin Tao (Newport Coast, CA); Qinwei Wang (Alhambra, CA); David Ho (Monterey Park, CA); Tulay Polat (Tustin, CA); Laxman Nallan (Rancho Mission Viejo, CA); Patrick Soon-Shiong (Los Angeles, CA)
Assignee: NantBio, Inc.
A61K31/506A61K31/5377A61K31/541C07D401/14C07D403/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,245,261
App. No.
15/379,696
Granted
Apr 2, 2019
Kind
B2
Abstract

The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.

Claims (16)

1. A method of treating cancer in a mammal, wherein the cancer is selected from the group consisting of Chronic Myelogenous Leukemia (CIVIL), Acute Myelogenous Leukemia (AML) and thyroid, endometrial, gastric, breast and pancreatic carcinoma, and wherein the method comprises administering to the mammal a therapeutically effective amount of a composition comprising NTW-3475, wherein NTW-3475 is the compound having the structure:

2. The method of claim 1 , wherein NTW-3475 is administered with other active agents.

3. The method of claim 1 , wherein NTW-3475 is administered with a carrier.

4. The method of claim 1 wherein the cancer is pancreatic carcinoma.

5. The method of claim 1 , wherein the administration of the composition results in reduced signal transduction by the pERK pathway.

6. The method of claim 1 , wherein the administration of the composition results in reduced signal transduction by the pERK pathway.

7. The method of claim 1 , wherein the mammal is human.

8. A method for reducing signal transduction by the pERK pathway in cells comprising contacting the cells with NTW-3475, wherein the cells are MiaPaCa-2 cells or BxPC3 cells, and wherein NTW-3475 is the compound having the structure:

9. The method of claim 8 , wherein the cells are in vivo.

10. The method of claim 8 , wherein the cells are human.

11. The method of claim 1 , wherein the cancer is CML.

12. The method of claim 1 , wherein the cancer is AML.

13. The method of claim 1 , wherein the cancer is thyroid carcinoma.

14. The method of claim 1 , wherein the cancer is endometrial carcinoma.

15. The method of claim 1 , wherein the cancer is gastric carcinoma.

16. The method of claim 1 , wherein the cancer is breast carcinoma.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: TAO, CHUNLIN; WANG, QINWEI; POLAT, TULAY; HO, DAVID; NALLAN, LAXMAN; SOON-SHIONG, PATRICK
To: NANTBIO, INC.
Reel/Frame 047217/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: TAO, CHUNLIN
To: NANTBIO, INC.
Reel/Frame 046678/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: NANT HOLDING IP, LLC
To: NANTBIO, INC.
Reel/Frame 046487/0901 →
CHANGE OF NAME Recorded Dec 12, 2017
From: NANTBIOSCIENCE, INC.
To: NANTBIO, INC.
Reel/Frame 044839/0167 →
CHANGE OF NAME Recorded Oct 23, 2017
From: NANTBIO, INC.
To: NANTBIOSCIENCE, INC.
Reel/Frame 044271/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: NANT HOLDINGS IP, LLC
To: NANTBIO, INC.
Reel/Frame 043554/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: TAO, CHUNLIN
To: NANT HOLDINGS IP, LLC
Reel/Frame 040946/0438 →
Continuity (3)
Continuation 14775434
Provisional Application 61852309 · Mar 15, 2013
Related Publication 20170189400A1 · Jul 6, 2017